Subscribe to RSS
DOI: 10.1055/s-2008-1081100
© Georg Thieme Verlag KG Stuttgart · New York
Kleine Antigene – große Wirkung
Die Rolle von Minor-Histokompatibilitätsantigenen bei der allogenen BlutstammzelltransplantationMinor antigens – major impactThe role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantationPublication History
eingereicht: 21.11.2007
akzeptiert: 6.3.2008
Publication Date:
02 July 2008 (online)

Zusammenfassung
Die allogene Blutstammzelltransplantation (HCT) ist oftmals die einzige kurative Behandlungsoption für Patienten mit malignen und nicht-malignen hämatologischen Erkrankungen. Nach der HCT richten sich immunologische, sogenannte Graft-versus-Leukämie (GvL)-Reaktionen gegen die bösartigen Zellen und tragen hocheffektiv zur Remission der Erkrankungen bei. Sowohl der GvL-Effekt, aber auch die Graft-versus-Host-Erkrankung (GvHD) werden nach HLA-identer HCT von Spender-T-Zellen vermittelt und resultieren aus Unterschieden der Minor Histokompatibilitätsantigene (mHag) zwischen Spender und Empfänger. GvL-Reaktionen können ebenfalls durch Tumor-spezifische immunogene Peptide ausgelöst werden, der Fokus soll in diesem Übersichtsartikel jedoch auf den mHag liegen. Wir möchten den aktuellen Kenntnissstand und am Beispiel des mHag HA-1 die daraus resultierenden therapeutischen Optionen vorstellen. Das mHag HA-1 ist das am besten erforschte mHag: es wird ausschließlich auf hämatopoetischen Zellen und aberrant auf einigen soliden Tumoren, nicht jedoch auf Zielzellen der GvHD exprimiert. Mit einer HA-1-spezifischen Immuntherapie wäre es möglich, den endogenen GvL-Effekt nach der HCT zu verstärken und selektiv HA-1-positive Leukämie- und Tumorzellen anzugreifen, ohne eine GvHD auszulösen. Das Spektrum einer möglichen therapeutischen Nutzung reicht von der Vakzinierung geeigneter Patienten- und Spenderpaare mit der immunogenen Variante des HA-1 Peptides, bis hin zur Applikation HA-1-spezifischer zytotoxischer T-Zellen (adoptive Immuntherapie).
Summary
Allogeneic hematopoietic cell transplantation (HCT) is often the only curative treatment option for patients with malignant and non-malignant hematological diseases. There is striking evidence that immunological Graft-versus-Leukemia (GvL)-reactions efficiently eradicate malignant cells after transplant. After HLA-matched HCT both the beneficial GvL-effect and the detrimental Graft-versus-Host Disease (GvHD) are mediated by donor derived T-cells specific for minor histocompatibility antigens (mHag) that differ between patient and stem cell donor. In addition, tumor-specific antigens can also be targeted and contribute to GvL-reactivity. This review summarizes the state-of-the-art knowledge on mHag and presents the potential therapeutical options on example of the mHag HA-1. HA-1 is currently the best characterized mHag and particularly attractive for immunotherapy due to the restricted expression on hematopoietic cells and on some solid tumors but not on cells involved during GvHD. This would allow amplifying the endogenous GvL-effect and selectively targeting malignant HA-1-positive cells without causing GvHD. HA-1-specific immunotherapy in eligible patient and donor pairs may range from vaccination with the immunogenic HA-1 peptide to the infusion of HA-1-specific cytotoxic T-cells (adoptive immunotherapy).
Schlüsselwörter
Allogene Blutstammzelltransplantation - Konditionierung mit reduzierter Intensität - Minor Histokompatibilitätsantigene - Graft-versus-Leukämie-Effekt - Graft-versus-Host-Erkrankung - GvHD
Key words
allogeneic hematopoietic cell transplantation - reduced intensity conditioning - minor histocompatibility antigens - graft-versus-leukemia-effect - graft-versus-host disease - GvHD
Literatur
- 1
Akatsuka Y, Nishida T, Kondo E. et al .
Identification of a polymorphic gene, BCL2A1,
encoding two novel hematopoietic lineage-specific minor histocompatibility
antigens.
J Exp Med.
2003;
197
1489-1500
MissingFormLabel
- 2
Al-Ali H K, Brand R, van Biezen A. et al .
A retrospective comparison of autologous
and unrelated donor hematopoietic cell transplantation in myelodysplastic
syndrome and secondary acute myeloid leukemia: a report on behalf
of the Chronic Leukemia Working Party of the European Group for
Blood and Marrow Transplantation (EBMT).
Leukemia.
2007;
21
1945-1951
MissingFormLabel
- 3
Apperley J F, Jones L, Hale G. et
al .
Bone marrow transplantation for patients with chronic
myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence
of graft-versus-host disease but may increase the risk of leukaemic
relapse.
Bone Marrow Transplant.
1986;
1
53-66
MissingFormLabel
- 4
Bregni M, Dodero A, Peccatori J. et al .
Nonmyeloablative conditioning followed
by hematopoietic cell allografting and donor lymphocyte infusions
for patients with metastatic renal and breast cancer.
Blood.
2002;
99
4234-4236
MissingFormLabel
- 5
Brickner A G, Evans A M, Mito J K. et al .
The PANE1 gene encodes a
novel human minor histocompatibility antigen that is selectively
expressed in B-lymphoid cells and B-CLL.
Blood.
2006;
107
3779-3786
MissingFormLabel
- 6
Brickner A G, Warren E H, Caldwell J A. et al .
The immunogenicity of a
new human minor histocompatibility antigen results from differential
antigen processing.
J Exp Med.
2001;
193
195-206
MissingFormLabel
- 7
Brouwer R E, Zwinderman K H, Kluin-Nelemans H C. et al .
Expression and induction
of costimulatory and adhesion molecules on acute myeloid leukemic
cells: implications for adoptive immunotherapy.
Exp Hematol.
2000;
28
161-168
MissingFormLabel
- 8
Chen B J, Cui X, Sempowski G D. et al .
Transfer of allogeneic CD62L- memory T
cells without graft-versus-host disease.
Blood.
2004;
103
1534-1541
MissingFormLabel
- 9
de Rijke B, van Horssen-Zoetbrood A, Beekman J M. et al .
A frameshift polymorphism
in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated
with remission of chronic myeloid leukemia.
J Clin Invest.
2005;
115
3506-3516
MissingFormLabel
- 10
den Haan J JM, Meadows L M, Wang W. et al .
The minor histocompatibility antigen HA-1:
a diallelic gene with a single amino acid polymorphism.
Science.
1998;
279
1054-1057
MissingFormLabel
- 11
Dickinson A M, Wang X N, Sviland L. et al .
In situ dissection of the graft-versus-host
activities of cytotoxic T cells specific for minor histocompatibility
antigens.
Nat Med.
2002;
8
410-414
MissingFormLabel
- 12
Dolstra H, de Rijke B, Fredrix H. et al .
Bi-directional allelic recognition of the
human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes.
Eur J Immunol.
2002;
32
2748-2758
MissingFormLabel
- 13
Eibl B, Schwaighofer H, Nachbaur D. et al .
Evidence for a graft-versus-tumor effect
in a patient treated with marrow ablative chemotherapy and allogeneic
bone marrow transplantation for breast cancer.
Blood.
1996;
88
1501-1508
MissingFormLabel
- 14
Falkenburg J H, Wafelman A R, Joosten P. et al .
Complete remission of accelerated phase
chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic
T lymphocytes.
Blood.
1999;
94
1201-1208
MissingFormLabel
- 15
Hambach L, Nijmeijer B A, Aghai Z. et al .
Human cytotoxic T lymphocytes specific
for a single minor histocompatibility antigen HA-1 are effective
against human lymphoblastic leukaemia in NOD/scid mice.
Leukemia.
2006;
20
371-374
MissingFormLabel
- 16
Heslop H E, Ng C Y, Li C. et al .
Long-term restoration of immunity against Epstein-Barr
virus infection by adoptive transfer of gene-modified virus-specific
T lymphocytes.
Nat Med.
1996;
2
551-555
MissingFormLabel
- 17
Klein C A, Wilke M, Pool J. et
al .
The hematopoietic system-specific minor histocompatibility
antigen HA-1 shows aberrant expression in epithelial cancer cells.
J Exp Med.
2002;
196
359-368
MissingFormLabel
- 18
Kolb H J, Schattenberg A, Goldman J M. et al .
Graft-versus-leukemia effect of
donor lymphocyte transfusions in marrow grafted patients.
Blood.
1995;
86
2041-2050
MissingFormLabel
- 19
Lin M T, Gooley T, Hansen J A. et al .
Absence of statistically significant correlation
between disparity for the minor histocompatibility antigen-HA-1
and outcome after allogeneic hematopoietic cell transplantation.
Blood.
2001;
98
3172-3173
MissingFormLabel
- 20
Mackensen A, Meidenbauer N, Vogl S. et al .
Phase I study of adoptive T-cell therapy
using antigen-specific CD8+ T cells for the treatment of
patients with metastatic melanoma.
J Clin Oncol.
2006;
24
5060-5069
MissingFormLabel
- 21
Marijt W A, Heemskerk M H, Kloosterboer F M. et al .
Hematopoiesis-restricted
minor histocompatibility antigens HA-1- or HA-2-specific T cells can
induce complete remissions of relapsed leukemia.
Proc
Natl Acad Sci U S A.
2003;
100
2742-2747
MissingFormLabel
- 22
Meadows L, Wang W, den H aan
JM. et al .
The HLA-A*0201-restricted
H-Y antigen contains a posttranslationally modified cysteine that
significantly affects T cell recognition.
Immunity.
1997;
6
273-281
MissingFormLabel
- 23
Mommaas B, Kamp J, Drijfhout J W. et al .
Identification of a novel HLA-B60-restricted
T cell epitope of the minor histocompatibility antigen HA-1 locus.
J Immunol.
2002;
169
3131-3136
MissingFormLabel
- 24
Niederwieser D, Maris M, Shizuru J A. et al .
Low-dose total body irradiation (TBI) and
fludarabine followed by hematopoietic cell transplantation (HCT)
from HLA-matched or mismatched unrelated donors and postgrafting
immunosuppression with cyclosporine and mycophenolate mofetil (MMF)
can induce durable complete chimerism and sustained remissions in
patients with hematological diseases.
Blood.
2003;
101
1620-1629
MissingFormLabel
- 25
Papadopoulos E B, Ladanyi M, Emanuel D. et al .
Infusions of donor leukocytes
to treat Epstein-Barr virus-associated lymphoproliferative disorders
after allogeneic bone marrow transplantation.
N Engl J
Med.
1994;
330
1185-1191
MissingFormLabel
- 26
Pierce R A, Field E D, Mutis T. et al .
The HA-2 minor histocompatibility antigen
is derived from a diallelic gene encoding a novel human class I myosin
protein.
J Immunol.
2001;
167
3223-3230
MissingFormLabel
- 27
Propper D J, Chao D, Braybrooke J P. et al .
Low-dose IFN-gamma induces tumor MHC expression
in metastatic malignant melanoma.
Clin Cancer Res.
2003;
9
84-92
MissingFormLabel
- 28
Riddell S R, Watanabe K S, Goodrich J M. et al .
Restoration of viral immunity
in immunodeficient humans by the adoptive transfer of T cell clones.
Science.
1992;
257
238-241
MissingFormLabel
- 29
Shlomchik W D, Couzens M S, Tang C B. et al .
Prevention of graft versus host
disease by inactivation of host antigen-presenting cells.
Science.
1999;
285
412-415
MissingFormLabel
- 30
Sorror M L, Maris M B, Sandmaier B M. et al .
Hematopoietic cell transplantation
after nonmyeloablative conditioning for advanced chronic lymphocytic
leukemia.
J Clin Oncol.
2005;
23
3819-3829
MissingFormLabel
- 31
Spierings E, Brickner A G, Caldwell J A. et al .
The minor histocompatibility antigen
HA-3 arises from differential proteasome-mediated cleavage of the
lymphoid blast crisis (Lbc) oncoprotein.
Blood.
2003;
102
621-629
MissingFormLabel
- 32
Spierings E, Hendriks M, Absi L. et al .
Phenotype frequencies of autosomal minor
histocompatibility antigens display significant differences among
populations.
PLoS Genet.
2007;
3
e103
MissingFormLabel
- 33
Sullivan K M, Weiden P L, Storb R. et al .
Influence of acute and chronic graft-versus-host
disease on relapse and survival after bone marrow transplantation
from HLA-identical siblings as treatment of acute and chronic leukemia.
Blood.
1989;
73
1720-1728
MissingFormLabel
- 34
Terakura S, Murata M, Warren E H. et al .
A single minor histocompatibility antigen
encoded by UGT2B17 and presented by human leukocyte antigen-A*2902
and -B*4403.
Transplantation.
2007;
83
1242-1248
MissingFormLabel
- 35
Torikai H, Akatsuka Y, Miyauchi H. et al .
The HLA-A*0201-restricted minor
histocompatibility antigen HA-1H peptide can also be presented by another
HLA-A2 subtype, A*0206.
Bone Marrow Transplant.
2007;
40
165-174
MissingFormLabel
- 36
Tykodi S S, Warren E H, Thompson J A. et al .
Allogeneic hematopoietic
cell transplantation for metastatic renal cell carcinoma after nonmyeloablative
conditioning: toxicity, clinical response, and immunological response
to minor histocompatibility antigens.
Clin Cancer Res.
2004;
10
7799-7811
MissingFormLabel
Dr. med. Michael Hudecek
Universitätsklinikum Leipzig, Department Hämatologie, Onkologie
und Gerinnung
Johannisallee 32a
04103 Leipzig
Phone: 0341/9713050
Fax: 0341/9713059
Email: m.hudecek@gmx.de